Interestingly, rivastigmine, the current Food and Drug Administration (FDA) approved cholinesterase inhibitor that exhibits potent dual acetyl- and butyryl-cholinesterase inhibitor activity [49], has neuropsychiatric side effects that overlap with those for MQ, including anxiety and depression [50], indicative of an influence of cholinergic mechanisms on mood and behaviour. This evidence concerns the gene BCHE and Anxiety.